UnknownPhase 2

STS Administration on Coronavirus Disease (COVID-19) Patients in Critical Care

Greece30 participantsStarted 2022-04-01

Plain-language summary

The primary purpose is to describe the safety of administration of three doses of STS to critically ill patients with confirmed COVID-19. A secondary purpose is to describe data on the clinical efficacy of administration of up to three doses of STS in critically ill patients with confirmed COVID-19.

Who can participate

Age range18 Years – 110 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age equal to or older than 18 years
✓. Both genders
✓. For women of childbearing potential, they must use or be willing to use a dual contraceptive method during the study.
✓. Written consent statement provided by the patient or his / her legal representative in case patients are unable to consent.
✓. Confirmed COVID-19 disease
✓. WHO-CPS 7 to 9
✓. Hospitalization in Intensive Care Unit
✓. Serum H2S levels less than 140 μM

Exclusion criteria

✕. Age less than 18 years
✕. Denial of written consent
✕. Decision not to resuscitate

What they're measuring

Comparison of treatment-emergent serious and non-serious adverse events between treatment groups.

Timeframe: Visit study day 28

Trial details

NCT IDNCT05277285

SponsorHellenic Institute for the Study of Sepsis

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-12-31

Contact for this trial

Evangelos Giamarellos-Bourboulis, MD, PhD

+302107480662 egiamarel@med.uoa.gr

View on ClinicalTrials.gov More COVID-19 trials